Citations

Clear

248 citation(s) found for "Bhatt, S".

Results From Airflow-3: Randomized, Double Blind, Sham Controlled Study of Targeted Lung Denervation in Patients With COPD
Criner, G.J., Sue, Richard, Ghattas, Christian , Guibert, Nicolas , Valipour, A., Cardenas, José De , Soto, Jose Soto , Slebos, Dirk‐Jan , Bhatt, Surya P. , Strange, Charlie , Degano, Bruno , Eisenmann, Stephan , Marquette, Charles‐Hugo , Sciurba, Frank C. , Shah, Pallav L.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3112-A3112

10.1164/ajrccm.2025.211.abstracts.a3112 Get It

Abstract Rationale: The D'Nerva Targeted Lung Denervation (TLD) System uses radiofrequency energy delivered bronchoscopically to the main bronchi to disrupt parasympathetic nerve innervation to the lung. AIRFLOW-3 clinical trial was a randomized, double blind, sham controlled study to determine the impact of TLD on COPD exacerbations. Methods: AIRFLOW-3 patients had symptomatic COPD (CAT ≥10) with moderate to very severe airflow obstruction (GOLD stage II-IV: 25% ≤ FEV1 ≤ 80% predicted, FEV1/FVC<0.70) and GOLD E status (≥2 moderate or ≥1 severe exacerbation in the prior 12 months) despite optimal medical therapy. The primary endpoint was a time-to-first event comparison of the probability of subjects having a moderate or severe exacerbation, between the Treatment arm (TLD + optimal medical therapy) and the Sham Control arm (optimal medical therapy). Results: 388 patients were randomized 1:1 at 32 clinical sites across the US, EU, and UK. Patients were 67.8 (SD 7.1) years of age, ex-smokers with a 46.7 (22.0) pack-year smoking history, and 41.0 (11.8) post bronchodilator FEV1% pred. SGRQ-C and CAT scores were 62.5 (17.0) and 23.6 (6.3), respectively. Over 90% of patients were on triple therapy (LAMA+LABA+ICS) at baseline and through 1 year of follow up. 42% of patients had prior-year COPD hospitalization(s). There was no difference between groups in the analysis of the primary endpoint. At 1 year, the sham arm exhibited a statistical decline in lung function (decrease in FEV1 and FVC) and worsening of gas trapping (increase in RV). Lung function and gas trapping were stable in the treatment arm. The treatment arm exhibited a statistically significant improvement in dyspnea at one year compared to sham (mMRC, and TDI). These observations led to the identification of a subgroup of TLD treatment responders corresponding to an airway predominant phenotype (lung hyperinflation in the absence of significant emphysema) that demonstrated clinically and statistically significant improvements in lung function and exacerbation frequency and severity (Table). Conclusions: The AIRFLOW-3 clinical trial failed to meet its prespecified primary endpoint. Post-hoc analysis of this robust dataset led to the identification of a responder profile that achieved significant and sustained improvements in lung function, and exacerbation reduction. A future clinical study is being designed to confirm these findings.
The 9th Version of the AJCC Staging System for Nasopharyngeal Carcinoma: A Guide for Radiologists
Lakhani, Dhairya A. , Lakhani, Dhairya , Rai, Pranjal , Agarwal, Amit , Bhatt, Alok A.

Mayo Clinic

American Journal of Roentgenology | April 30, 2025 | Volume: 225 | Issue: 2 | Pages: No page available

10.2214/ajr.25.33016 | PMID 40304669 Get It

Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704
Sorror, Mohamed L. , Saber, Wael , Logan, Brent R. , Geller, Nancy L. , Bellach, Anna , Kou, Jianqun, McCarty, John M. , Knight, Thomas G. , Runaas, Lyndsey, Johnston, Laura, Nakamura, Ryotaro , Jarrett, Lori, Mishra, Asmita , Uberti, Joseph P., Morris, Lawrence E. , Nadiminti, Kalyan , Olin, Rebecca L. , Sobecks, Ronald , Wall, Sarah , Mattila, Deborah, Protz, Bailey, Horowitz, Mary M. , Geller, Nancy , Knight, Thomas G , Nakamura, Ryotaro , Dahi, Parastoo B , Saultz, Jennifer N , Imus, Philip H , Hogan, William J , Bhatt, Vijaya Raj , Artz, Andrew S , Sorror, Mohamed , Wood, William A. , Walston, Jeremy D , Jarrett, Lori, McCurdy, Shannon , Hogan, William J. , Bhatt, Vijaya Raj , Maakaron, Joseph E. , Devine, Steven M. , Artz, Andrew

Mayo Clinic

Blood Advances | March 18, 2025 | Volume: 9 | Issue: 13 | Pages: 3268-3280

10.1182/bloodadvances.2025015793 | PMID 40101246 Get It

Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for older adults with hematologic malignancies. Concerns on nonrelapse mortality (NRM) in older adults limit allo-HCT utilization. We executed a prospective, observational study BMT-CTN 1704 (Blood and Marrow Transplant Clinical Trials Network) enrolling allo-HCT recipients aged ≥60 years from 49 centers in the United States. We analyzed associations between 13 measurements of older adult health and NRM within 1 year to construct a comprehensive health assessment risk model (primary-CHARM) using multivariate Fine-Gray model and grouped penalized variable selection. Two machine learning (ML) models (Cox and pseudo-value boosting) were also explored. Models’ performances were compared using area under the curve (AUC), with bootstrap and cross-validation sampling to correct for optimism, decision curve analysis (DCA), calibration, and Brier scores. Among 1105 patients with median age of 67 (range, 60-82) years who received allo-HCT, NRM was 14.4% and overall survival (OS) 71.7% at 1 year. Factors statistically selected for inclusion in primary-CHARM were higher comorbidity burden, lower albumin, higher C-reactive protein, older age, higher weight-loss percentage, lower patient-reported performance score, and cognitive impairment. Primary-CHARM scores were independently associated with higher NRM (hazard ratio [HR], 2.72; P < .0001) and worse OS (HR, 2.09; P < .0001). Bootstrap bias–corrected AUC for primary-CHARM was 0.591. Comparing primary-CHARM with HCT-comorbidity index and 2 ML-CHARM models, calibration, Brier score, and DCA analysis favored primary-CHARM. Primary-CHARM, with mostly simple and readily available parameters, risk stratifies older adults for allo-HCT. Adopting primary-CHARM in practice may promote broader use of HCT by quantifying risk and enhance the design of strategies to improve outcomes. This trial was registered at www.ClinicalTrials.gov as #NCT03992352.
Journey to complete remission of dysplasia and intestinal metaplasia after ESD and EMR of Barrett’s esophagus-related neoplasia
Joseph, Abel , Vantanasiri, Kornpong , Garg, Nikita , Codipilly, Don C. , Wang, Kenneth T. , Harmsen, William S. , Jang, Sunguk, Iyer, Prasad G. , Bhatt, Amit, Bhatt, Amit , Leggett, Cadman, Iyer, Prasad, Bhatt, Amit , Goyal, Rohit, Leggett, Cadman L. , Vargo, John Joseph

Mayo Clinic

Endoscopy International Open | March 18, 2025 | Volume: 13 | Issue: CP | Pages: No page available

10.1055/a-2422-2815 | PMID 40376017 Get It

AbstractAlthough endoscopic submucosal dissection (ESD) is associated with higher en-bloc and R0 resection rates than cap-assisted endoscopic mucosal resection (cEMR), its comparative impact on achieving complete remission of dysplasia (CRD) and intestinal metaplasia (CRIM) in BE endoscopic eradication therapy (EET) is not well defined. We aimed to compare the journey of patients from initial endoscopic resection (ER) with ESD and cEMR to achieving CRD and CRIM.Patients undergoing ESD or cEMR followed by ablation for BE neoplasia at two academic institutions in the United States were included. Primary outcomes included CRD and CRIM rates following ER in the two groups. Secondary outcomes included the number of resection/ablative procedures from initial ER to achieving CRD and CRIM. Inverse probability treatment weighting (IPTW) was used to balance confounding variables between groups.A total of 801 patients (606 cEMR, 195 ESD) were included. ESD group patients had higher en-bloc resection rates (ESD 94.4%, cEMR 44.7%). Higher rates of CRD were observed in patients undergoing initial ESD (HR 1.53, P < 0.01). With time-to-event and IPTW analyses, rates of achieving CRD and CRIM were comparable between the groups. There were no significant differences in mean number of endoscopic resection or ablative procedures among patients undergoing initial cEMR resection compared with those treated with initial ESD.Despite larger lesion sizes and more cancers in patients undergoing ESD, the EET journey to achieving CRD and CRIM was comparable to that in patients receiving cEMR. Prospective studies are required to further study differences between these two treatment approaches.
Longitudinal Outcomes in Pi*MZ Alpha-1 Antitrypsin–Deficient Individuals with Tobacco Smoking History from the SPIROMICS Cohort
Barjaktarević, Igor , Hixson, Roxana, Zhuang, Zian , Buhr, Russell G. , Tejwani, Vickram , Barr, R. Graham, Bateman, Lori A. , Bhatt, Surya P. , Bleecker, Eugene R. , Cooper, Christopher B., Fortis, Spyridon , Hansel, Nadia N. , Hoffman, Eric A. , Martinez, Fernando J., Meyers, Deborah A., Paine, Robert, Pirozzi, C.S. , Sandhaus, Robert A. , Tashkin, Donald P., Wells, J. Michael , Woodruff, Prescott G. , Ortega, Victor E. , Drummond, M Bradley , Fortis, Spyridon , Hoffman, Eric A , Wells, J Michael , Barjaktarevic, Igor , Buhr, Russell G , Bhatt, Surya P , Barr, R. Graham, Curtis, Jeffrey L. , Drummond, Michael , Ghosh, Auyon , Han, MeiLan King , Ohar, Jill , Meyers, Deborah A. , Strange, Charlie

Mayo Clinic

Annals of the American Thoracic Society | March 11, 2025 | Volume: 22 | Issue: 7 | Pages: 998-1008

10.1513/annalsats.202411-1209oc | PMID 40068143 Get It

Abstract Rationale Reliable data about the natural history of lung function decline in alpha-1 antitrypsin (AAT)-deficient Pi*MZ heterozygotes is largely missing. Objectives We hypothesized that, in adults with a tobacco smoking history, lung function deteriorates faster in Pi*MZ compared with the Pi*MM genotype. Methods We identified 1,856 Pi*MM and 79 Pi*MZ participants with ⩾20 pack-years tobacco smoking history from the SPIROMICS (Subpopulations and Intermediate Outcomes Measures in COPD Study) cohort by DNA sequencing and followed them over a median of 4.8 years, comparing radiographic and clinical characteristics between the two groups over time using regression models. Results Adjusted for age, sex, race, smoking pack-year history, and smoking status, Pi*MZ participants had a lower baseline percent predicted forced expiratory volume in 1 second (FEV1) (65.4% vs. 75.1%; difference 95% confidence interval [CI], −15.4% to −3.9%), more radiographic emphysema (&lt;−950 Hounsfield units%, 12.9% vs. 7.8%; difference 95% CI, 2.8% to 7.5%), and nonsignificantly lower lung density. In the longitudinal analysis, the FEV1 annual rate of decline was similar in both groups over the course of the study (−34.5 ml/yr vs. −34.6 ml/yr for Pi*MZ and Pi*MM; difference 95% CI, −16.9 to 17.1 ml/yr). There were no significant differences between Pi*MZ and Pi*MM individuals in the annualized change in lung density, emphysema, patient-reported outcomes, exacerbations, or survival. The proportion with faster FEV1 decline (annual loss ⩾40 ml) was similar in Pi*MZ and Pi*MM groups. In both groups, faster FEV1 decline was associated with more air trapping and small airway disease at baseline. In Pi*MZ only, faster decline was associated with higher blood eosinophil counts (310 vs. 220 cells/μl; difference 95% CI, 30 to 140 cells/μl). In the subgroup analysis limited to a small number of currently smoking participants, no significant differences in longitudinal outcomes were found. Conclusions Despite a lower FEV1 and more emphysema at enrollment, the longitudinal analysis did not demonstrate significantly greater lung function decline or lung density loss in Pi*MZ compared with Pi*MM participants with tobacco smoking history. Limited sample size and duration of longitudinal follow-up constrain generalizability of our findings, thus prohibiting the conclusion that longitudinal trajectories did not differ between these groups. However, our results may suggest that earlier life events could be responsible for more extensive lung disease at enrollment in Pi*MZ compared with Pi*MM tobacco-exposed individuals.
Surgical Management of a Painful Temporal Bone En-Plaque Meningioma: A Case Report and Review of the Literature
Wilson, Prishae, Edgar, Mark A. , Quiñones‐Hinojosa, Alfredo , Raymond, Mallory , Wilson, Prishae, Bhatt, Alok A. , Almeida, João Paulo , Raymond, Mallory J

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803674 Get It

Cystic Breast Disease: What to Do When It’s Not So Cystic
Bhatt, Asha A. , Harper, Laura K , Anderson, Sarah , Solanki, Malvika , Ataya, Dana, Solanki, Malvika H

Mayo Clinic

Journal of Breast Imaging | January 15, 2025 | Volume: 7 | Issue: 2 | Pages: 233-248

10.1093/jbi/wbae079 | PMID 39809305 Get It

Abstract Cystic breast masses are a common entity encountered by breast radiologists. The imaging features of benign and malignant cystic masses may overlap, causing confusion and miscategorization with the potential to produce diagnostic delay and harm. This article provides a review of key differentiating imaging features that help guide appropriate mass characterization and treatment.
Physicians-in-training and advanced practice providers perceptions in managing perioperative obstructive sleep apnea: a multi-institutional survey
Lyons, M. Melanie , Auckley, Dennis , Charchaflieh, Jean , Myers, John V., Yılmaz, Meltem , Williams, Lisa , Khan, Meena , Card, Elizabeth , Gelfand, Brian J., Pilla, Michael A., Loftsgard, Theodore O. , Sawyer, Amy M. , Matura, Lea Ann , Carlucci, Melissa , Sahni, Ashima , Glaser, Kathleen, Ghussain, Dana E. Al, Bhatt, Nitin, Rosen, Ilene M. , Gali, Bhargavi , Mokhlesi, Babak , Ghussain, Dana Al, Brock, Guy , Magalang, Ulysses J

Mayo Clinic

Journal of Clinical Sleep Medicine | December 31, 2024 | Volume: 21 | Issue: 5 | Pages: 765-773

10.5664/jcsm.11528 | PMID 39745490 Get It

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies
Davids, Matthew S. , Brander, Danielle M. , Alvarado, Yesid , Egan, Daniel Nathan, Dinner, Shira, Malki, Monzr M. Al , Begna, Kebede H. , Bhatt, Vijaya Raj , Abedin, Sameem , Cook, Rachel J. , Collins, Mary C. , Roleder, Carly , Rajagopalan, Prabhu , Danilov, Alexey V., Alvarado-Valero, Yesid , Diefenbach, Catherine S , Egan, Daniel N , Dinner, Shira N , Javidi-Sharifi, Nathalie , Al Malki, Monzr M , Begna, Kebede , Bhatt, Vijaya Raj , Abedin, Sameem , Cook, Rachel J , Collins, Mary C , Roleder, Carly , Dominguez, Edward C , Rajagopalan, Prabhu , Wiley, Sandra E , Ghalie, Richard G , Danilov, Alexey V , Davids, Matthew S , Diefenbach, Catherine , Egan, Daniel

Mayo Clinic

Blood Advances | December 20, 2024 | Volume: 9 | Issue: 4 | Pages: 820-832

10.1182/bloodadvances.2024014633 | PMID 39705540 Get It

Abstract The antiapoptotic protein, myeloid cell leukemia-1 (Mcl-1), contributes to the pathophysiology of acute myeloid leukemia (AML) and certain B-cell malignancies. Tumor dependence on Mcl-1 is associated with resistance to venetoclax. Voruciclib, an oral cyclin-dependent kinase (CDK) inhibitor targeting CDK9, indirectly decreases Mcl-1 protein expression and synergizes with venetoclax in preclinical models. This dose escalation study evaluated voruciclib in patients with previously treated hematologic malignancies. Initially, voruciclib was administered daily, continuously, on a 28-day cycle (group 1). After 2 patients with prior allogeneic stem cell transplantation had a dose-limiting toxicity (DLT) of interstitial pneumonitis at 100 mg, voruciclib administration was changed to days 1 to 14 of a 28-day cycle (group 2). Forty patients, 21 with AML and 19 with B-cell malignancies, were enrolled. Patients had a median of 3 prior lines of therapy (range, 1-8). Dose escalation in group 2 was stopped at 200 mg, a dose that achieved plasma concentrations sufficient for target inhibition, without DLTs observed. The most common adverse events were diarrhea (30%), nausea (25%), anemia (22%), fatigue (22%), constipation (17%), dizziness (15%), and dyspnea (15%). In AML, 1 patient achieved a morphologic leukemia-free state, and 2 had stable disease. Voruciclib treatment led to a decrease in MCL1 messenger RNA expression, downregulation of myelocytomatosis (MYC) and NF-κB transcriptional gene sets, and reduced phosphorylation of RNA polymerase 2. Voruciclib on intermittent dosing was well tolerated, with no DLTs, paving the way for evaluation of the combination of voruciclib with venetoclax for patients with previously treated AML. This trial was registered at www.clinicaltrials.gov as #NCT03547115.
A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Alvarado‐Valero, Yesid, Cook, Rachel J. , Dinner, Shira, Keng, Michael , Begna, Kebede H. , Abedin, Sameem , Malki, MHD Monzr M. Al, Rajagopolan, Prabhu, Abedin, Sameem , Bhatt, Vijaya Raj , Javidi-Sharifi, Nathalie , Wiley, Sandra E , Ghalie, Richard G , Davids, Matthew S.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 2878-2878

10.1182/blood-2024-198718 Get It

Background: Venetoclax in combination with hypomethylating agents (HMA) or low dose cytarabine is the standard of care for patients (pts) with newly diagnosed AML ineligible for intensive chemotherapy. However, responses are transient, and loss of response is associated with poor outcome. The antiapoptotic protein Mcl-1 promotes cell survival in AML and its overexpression is associated with resistance to venetoclax. Voruciclib, a potent oral CDK9 inhibitor (CDK9i), indirectly decreases Mcl-1 protein expression, and has synergistic activity with venetoclax in AML preclinical models. In the initial part of this study in 40 pts with R/R AML and B-cell malignancies, voruciclib at doses up to 200 mg administered on days 1-14 in a 28-day cycle was well tolerated, had no dose limiting toxicities (DLTs), and showed biologic and clinical activity in heavily pretreated pts (Blood 2023:142; Supp 1:4286). We hypothesized that voruciclib in combination with venetoclax may achieve greater antileukemic effect. Methods: Pts with R/R AML were eligible if aged ≥18 years, ECOG performance status ≤1, adequate organ function, and no prior CDK9i therapy. Dose escalation followed a 3+3 design, and DLTs were assessed in Cycle 1. Voruciclib was administered at 7 dose levels between 50 mg and 300 mg on days 1-14 of 28-day cycles. Venetoclax was administered at 200 mg on days 1-21 and 400 mg on days 22-28. Disease response was assessed by the 2017 ELN criteria. Mcl-1 protein expression and phosphorylation of RNA Pol IISer2 were evaluated in PBMC in cycle 1. The study is registered at clinicaltrials.gov (NCT03547115). Results: Enrollment in this portion of the study is complete with 41 pts. Median age was 67 years (range 34-89). Median number of prior lines of therapy was 2 (range 1-7), with 93% of pts having received venetoclax and HMAs, 51% having received an anthracycline, and 20% having had prior allogeneic hematopoietic stem cell transplant (HSCT). 2017 ELN risk was adverse in 73% of pts and intermediate in 17%. The median duration on therapy was 1.5 months (range 0.2 to 9+). No DLTs were observed, and based on PK/PD analysis, dose escalation was stopped at 300 mg without reaching the maximum tolerated dose. The most common adverse events (all grades/grade ≥3) were nausea (32%/0%), febrile neutropenia (27%/24%), dyspnea (22%/2%) diarrhea (22%/2%), hypokalemia (22%/5%) and thrombocytopenia (22%/20%). Seven pts died during treatment, 5 due to an infection and 2 due to hemorrhagic events. Anti-leukemic activity was observed in 10 (31%) of 32 pts treated with voruciclib at doses from 100-300 mg; 2 pts had CRi (one referred to HSCT and one with 6 months of remission prior to progression), 1 pt had MLFS (ongoing at 9 months), and 7 pts had stable disease lasting ≥3 months. Among 25 pts with circulating peripheral blood blasts, 18 (75%) showed a significant reduction of circulating blasts by day 14 of the first cycle; however, circulating blasts increased again in 8 of 18 pts during single agent venetoclax administration on days 15 to 28. Voruciclib pharmacokinetics (PK) was dose proportional. At 300 mg steady state, mean AUC0-24 was 21,526 ng x hr/mL and mean Ctrough was 644 ng/mL, exceeding concentrations needed for target inhibition in preclinical models. Voruciclib did not affect venetoclax PK. Pharmacodynamic studies including Mcl-1 protein expression and RNA Pol IISer2 phosphorylation in PBMC by flow cytometry showed on target effects and is reported separately. Conclusion: The combination of voruciclib with venetoclax is well-tolerated and has activity in pts with AML and disease progression after venetoclax. Because of the rebound in peripheral blasts after 14 days off voruciclib, voruciclib administered on days 1-21 per cycle merits further evaluation.